<DOC>
	<DOCNO>NCT00002988</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness irinotecan plus carmustine treating patient recurrent primary malignant glioma .</brief_summary>
	<brief_title>Irinotecan Plus Carmustine Treating Patients With Recurrent Primary Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose irinotecan administer combination fix dose carmustine patient recurrent primary malignant glioma . II . Determine toxic effect irinotecan carmustine patient . OUTLINE : This dose escalation study irinotecan . Patients receive irinotecan IV 90 minute weekly week 1-4 carmustine IV 1 hour week 1-6 . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose 1 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 18-36 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent primary malignant glioma Measurable recurrent residual primary central nervous system neoplasm confirm MRI PATIENT CHARACTERISTICS : Age : 18 Performance Status : Karnofsky 60100 % Hematopoietic : Hematocrit great 29 % Absolute neutrophil count great 1,500/mm3 Platelet count great 125,000/mm3 Hepatic : SGOT le 1.5 time upper limit normal ( ULN ) Bilirubin le 1.5 time ULN Renal : Creatinine le 1.5 mg/dL BUN le 25 mg/dL Pulmonary : DLCO least 60 % Other : Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 week since prior chemotherapy No prior irinotecan carmustine treatment failure No 1 prior chemotherapy regimen Endocrine therapy : Patients take corticosteroid must stable dose least 1 week prior study dose escalate entry dose level Radiotherapy : At least 6 week since prior radiotherapy Surgery : At least 3 week since prior surgical resection Other : No concurrent medication may interfere study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
</DOC>